Achiko

Achiko AG (SIX: ACHI.SW) is developing disruptive diagnostic solutions that put people first.

[Achiko @achikoag]

As Achiko is proceeding to sales and is currently going through external validation, we are proud to report that early results indicate AptameX's strong performance against other forms of #COVID19 testing. See the test performance here: https://t.co/P1dmdpNBXG

[Achiko @achikoag]

Achiko held its Annual General Meeting on December 20 and is pleased to announce that all resolutions were duly passed. The Board of Directors would like to thank all those who exercised their rights as shareholders in this way. Details can be found here: https://t.co/k1dJ8OjqLc

[Achiko @achikoag]

Achiko issues a convocation notice to its shareholders for its Annual General Meeting on 20 December 2022. https://t.co/sgX0rbMwnI

#achiko #agm2022 #annualgeneralmeeting

[Achiko @achikoag]

Achiko will be holding a corporate update webcast for all shareholders and investors on Tuesday, November 22, 2022 at 3.00pm CET/9.00am EST. Details of the webcast can be found here: https://t.co/ANl6iR0tVl

#healthtechnology #shareholder #investor #webcast

[Achiko @achikoag]

Following pilot production with manufacturing partner @indofarmaid, @achikoag is now commencing commercial deliveries of the Company's Generation 2 AptameX™ #Covid19 test kit to Nahdlatul Ulama DKI (NU) and other commercial clients in #Indonesia
Read: https://t.co/lloxIHLSXP

[Achiko @achikoag]

Achiko has successfully completed a production test with PT Indofarma, Tbk @indofarmaid as a precursor to mass production of the Company's Generation 2 AptameX™ Covid-19 test kit. More here ➡️ https://t.co/9tLX5D0D93
#indonesia #covidtesting #healthtech

[Achiko @achikoag]

“We are excited to welcome Lars on board,” said Mr Steven Goh, CEO of Achiko AG. “It’s the start of a process to build an exec team and Board with Swiss representation and is a decisive step towards the Company’s final transformation into becoming a diagnostics & tech company.”

[Achiko @achikoag]

@Achiko announces the appointment of Mr Lars Birkmann as Chief Financial Officer. More here: https://t.co/w4DJbS8OJQ

#achiko #cfo #healthtech

[Achiko @achikoag]

“We are grateful to our shareholders and our partners for their help and support and look forward to a brighter finish to 2022 and beyond,” Achiko CEO @crazygrape Steven Goh said.

[Achiko @achikoag]

Achiko announces its financial results for the period of 6 months to 30 June 2022. https://t.co/VL1Ove8ick #aptamex #temansehat

[Achiko @achikoag]

Despite another challenging period for the Company, it has made significant progress with its initial commercial application of its AptameX™ technology and expects to be generating significant revenue from AptameX™ in Indonesia in the final quarter of 2022.

[Achiko @achikoag]

(2) Achiko Corporate and Operational Update: https://t.co/cIknIXDCUH
✅Successful calibration of Generation 2 #AptameX™ product
✅Steven Goh, CEO, to step down upon appointment of successor but will remain a company exec, overseeing commercialisation efforts particularly in Asia

[Achiko @achikoag]

(1) Achiko Corporate and Operational Update: https://t.co/cIknIXDCUH
✅ACHI shares resumed trading on SIX Swiss Exchange on 1 September after successful completion of Audit and Financing
✅Key Swiss investors provide CHF 1.3 million via convertible notes

[Achiko @achikoag]

Achiko will publish its 2021 annual report on 31 August 2022 at the latest. More information can be found here: https://t.co/SQSb8h4IL2 #achiko #aptamex #annualreport

[Achiko @achikoag]

.... With this financing we’re in a position to drive sales and do some good.”

[Achiko @achikoag]

(1) Achiko announces the completion of a CHF 1.25 million financing with strategic investors Buranto AG and @Negma_Group and is pleased to welcome Mr Derek Brandt to the Advisory Board. https://t.co/40nSLDnEK2

[Achiko @achikoag]

“We’re excited and grateful to our shareholders, old and new”, said Steven Goh @crazygrape, CEO of Achiko “#Covid19 is going to be with us a long time & the unique performance and customer experience characteristics of the company...

[Achiko @achikoag]

“This is the first major mainstream use of #DNA #aptamers in a consumer testing product and a fantastic milestone for Achiko”, stated Steven Goh @crazygrape, CEO of Achiko. #covid19 #covidtest

[Achiko @achikoag]

(1) #Achiko is pleased to announce that it has successfully registered #AptameX™ under the European Union’s Medical Device Research (MDR) and In Vitro Diagnostic Regulation (IVDR), and has obtained a CE Mark that grants it access to 27 countries in the EU https://t.co/ywkHOWkK8O

[Achiko @achikoag]

Following last week's announcement, Achiko is pleased to report stronger than expected demand for AptameX and is planning to deliver over 2 million kits in a shorter timeframe than previously contemplated to meet demand, and is commencing first deliveries. https://t.co/fg4Aejl8fE